Pharmacy Technician’s Letter addresses the issues facing pharmacy technicians. For example: What is Intuniv (guanfacine extended-release), and how does guanfacine work for ADHD? Where does it fit into therapy for ADHD and who would you use it for? What’s the niche for Intuniv? How does it compare to stimulants? What are the major side effects? What’s the cost? How well does Intuniv work?

For answers see our article: Intuniv (in-TOO-niv), a new extended-release guanfacine for ADHD in kids

	Login if you are a current subscriber to Pharmacy Technician's Letter.
	Subscribe now to get instant access and the answers you need.

Additional information is available in our Detail-Document:
	Drug Treatment for Attention-Deficit / Hyperactivity Disorder
	Attention-deficit/hyperactivity disorder (ADHD) affects approximately 4% to 12% of all school age children in the U.S. Psychostimulants or Strattera are considered first-line pharmacotherapy for ADHD unless there are contraindications. The FDA recently approved Intuniv (guanfacine extended-release tablets) for the treatment of ADHD. This document provides a chart comparing the FDA-approved ADHD drug treatments (e.g., cost, dosing, duration of action, etc). Read more...